Annexon raises $44M in B round

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $44 million in a series B round led by new investor New Enterprise Associates. New investor Correlation Ventures also participated, as did existing investors including Novartis Venture Fund, Clarus and Satter Investment Management.

Annexon is developing inhibitors of the classical complement pathway to treat neurodegenerative, autoimmune and ophthalmic diseases. Its lead programs are mAbs that inhibit complement component 1 q subcomponent ( C1q). ...